References
- Iwata D, Namba K, Yamamoto T, Mizuuchi K, Saito W, Ohno S, Kitaichi N, Ishida S. Recent clinical features of intraocular inflammation in Hokkaido, Japan - comparison with the previous decade. Ocul Immunol Inflamm. 2021;1–7. doi:https://doi.org/10.1080/09273948.2020.1836565.
- Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M, Sugita S, Ueno S, Yoshizaki K, Inaba G. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet’s disease with refractory uveoretinitis. J Rheumatol. 2004;31:1362–68.
- Erckens RJ, Mostard RL, Wijnen PA, Schouten JS, Drent M. Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol. 2012;250(5):713–20. doi:https://doi.org/10.1007/s00417-011-1844-0.
- Interlandi E, Leccese P, Olivieri I, Latanza L. Adalimumab for treatment of severe Behcet’s uveitis: a retrospective long-term follow-up study. Clin Exp Rheumatol. 2014;32:S58–62.
- Couto C, Schlaen A, Frick M, Khoury M, Lopez M, Hurtado E, Goldstein D. Adalimumab treatment in patients with Vogt-Koyanagi-Harada disease. Ocul Immunol Inflamm. 2018;26(3):485–89. doi:https://doi.org/10.1080/09273948.2016.1236969.
- Namba K, Kitaichi N, Nishida T, Taylor AW. Induction of regulatory T cells by the immunomodulating cytokines alpha-melanocyte-stimulating hormone and transforming growth factor-beta2. J Leukoc Biol. 2002;72:946–52.
- Usui Y, Takeuchi M, Hattori T, Okunuki Y, Nagasawa K, Kezuka T, Okumura K, Yagita H, Akiba H, Goto H. Suppression of experimental autoimmune uveoretinitis by regulatory dendritic cells in mice. Arch Ophthalmol. 2009;127(4):514–19. doi:https://doi.org/10.1001/archophthalmol.2009.34.
- Yang H, Feng R, Fu Q, Xu S, Hao X, Qiu Y, Feng T, Zeng Z, Chen M, Zhang S. Human induced pluripotent stem cell-derived mesenchymal stem cells promote healing via TNF-alpha-stimulated gene-6 in inflammatory bowel disease models. Cell Death Dis. 2019;10(10):718. doi:https://doi.org/10.1038/s41419-019-1957-7.
- Sasaki H, Wada H, Baghdadi M, Tsuji H, Otsuka R, Morita K, Shinohara N, Seino K. New immunosuppressive cell therapy to prolong survival of induced pluripotent stem cell-derived allografts. Transplantation. 2015;99(11):2301–10. doi:https://doi.org/10.1097/TP.0000000000000875.
- Takahashi K, Okita K, Nakagawa M, Yamanaka S. Induction of pluripotent stem cells from fibroblast cultures. Nat Protoc. 2007;2(12):3081–89. doi:https://doi.org/10.1038/nprot.2007.418.
- Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663–76. doi:https://doi.org/10.1016/j.cell.2006.07.024.
- Wada H, Kojo S, Kusama C, Okamoto N, Sato Y, Ishizuka B, Seino K. Successful differentiation to T cells, but unsuccessful B-cell generation, from B-cell-derived induced pluripotent stem cells. Int Immunol. 2011;23(1):65–74. doi:https://doi.org/10.1093/intimm/dxq458.
- Nakano T, Kodama H, Honjo T. Generation of lymphohematopoietic cells from embryonic stem cells in culture. Science. 1994;265(5175):1098–101. doi:https://doi.org/10.1126/science.8066449.
- Thurau SR, Chan CC, Nussenblatt RB, Caspi RR. Oral tolerance in a murine model of relapsing experimental autoimmune uveoretinitis (EAU): induction of protective tolerance in primed animals. Clin Exp Immunol. 1997;109(2):370–76. doi:https://doi.org/10.1046/j.1365-2249.1997.4571356.x.
- Itoh Y, Kajino K, Ogasawara K, Takahashi A, Namba K, Negishi I, Matsuki N, Iwabuchi K, Kakinuma M, Good RA, et al. Interaction of pigeon cytochrome c-(43-58) peptide analogs with either T cell antigen receptor or I-Ab molecule. Proc Natl Acad Sci U S A. 1997;94(22):12047–52. doi:https://doi.org/10.1073/pnas.94.22.12047.
- Wu Y, Lin G, Sun B. IRBP-specific Th1 cells from peripheral blood were predominant in the experimental autoimmune uveitis. Biochem Biophys Res Commun. 2003;302(1):150–55. doi:https://doi.org/10.1016/S0006-291X(03)00129-3.
- Xu H, Rizzo LV, Silver PB, Caspi RR. Uveitogenicity is associated with a Th1-like lymphokine profile: cytokine-dependent modulation of early and committed effector T cells in experimental autoimmune uveitis. Cell Immunol. 1997;178(1):69–78. doi:https://doi.org/10.1006/cimm.1997.1121.
- Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, Weaver CT. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005;6(11):1123–32. doi:https://doi.org/10.1038/ni1254.
- Rangachari M, Mauermann N, Marty RR, Dirnhofer S, Kurrer MO, Komnenovic V, Penninger JM, Eriksson U. T-bet negatively regulates autoimmune myocarditis by suppressing local production of interleukin 17. J Exp Med. 2006;203(8):2009–19. doi:https://doi.org/10.1084/jem.20052222.
- Muraille E, Leo O. Revisiting the Th1/Th2 paradigm. Scand J Immunol. 1998;47(1):1–9. doi:https://doi.org/10.1111/j.1365-3083.1998-47-1.00383.x.
- Cottrez F, Groux H. Regulation of TGF-beta response during T cell activation is modulated by IL-10. J Immunol. 2001;167(2):773–78. doi:https://doi.org/10.4049/jimmunol.167.2.773.
- Kehrl JH, Wakefield LM, Roberts AB, Jakowlew S, Alvarez-Mon M, Derynck R, Sporn MB, Fauci AS. Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med. 1986;163(5):1037–50. doi:https://doi.org/10.1084/jem.163.5.1037.
- Bingisser RM, Tilbrook PA, Holt PG, Kees UR. Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway. J Immunol. 1998;160:5729–34.
- Doi T, Ando M, Akaike T, Suga M, Sato K, Maeda H. Resistance to nitric oxide in Mycobacterium avium complex and its implication in pathogenesis. Infect Immun. 1993;61(5):1980–89. doi:https://doi.org/10.1128/iai.61.5.1980-1989.1993.